Outside World of COVID-19, Moderna Trending Up on News of “Noble-Prize” Worthy Vaccine

It’s been a wild 12 months for Moderna (MRNA), the drugmaker who’s been smack dab in the center of the COVID-19 vaccine conversation since last spring.

Shortly after Pfizer (PFE) and BioNTech (BNTX) debuted their vaccine in early December, Moderna came to market a week later, and still remains one of the only two vaccines approved in the U.S. to help prevent infection of COVID-19.

Despite the fact that Moderna is only one of two options to combat the pandemic in the U.S., shares of the drugmaker’s stock have been on quite the roller coaster ride over the past few months. As of Wednesday, shares of Moderna were more than 22% lower than their all-time highs set just about two weeks ago.

But, since then the company’s stock has been trending up again, currently riding a 5% rally from its Wednesday low… all on the heels of news that has nothing to do with COVID-19, according to CNBC.’s Jim Cramer who revealed Moderna is nearing the development of a vaccine that could protect against certain forms of cancer:

“This is not an RNA messenger vaccine company for COVID. This is a new way to be able to stop diseases and people I know that are working with this company know that they may have a vaccine against certain forms of cancer. That’s how powerful RNA messenger is. I’ve been reluctant to say that but I have it from more than one source. I have it from two sources, both of whom are involved … and it’s just incredible. We’re taking about a Noble Prize. It works.”

“Noble Prize” is about as much hype as you can pump into a story about a potential cancer vaccine. If reports from Cramer’s sources are accurate, this could be a massive breakthrough for Moderna and a potential juggernaut in the world of drug stocks.

See Comments (4)

Market Overview

Leave a Reply

Your email address will not be published. Required fields are marked *


Comments (4)

  1. Hugh Manatee

    Moderna have been working on mRNA “vaccines” for some while, but have never managed to bring any product to market, prior to the Covid “vaccine”. This remains unapproved: it currently has emergency authorization only. It should be noted that it is patented as “gene therapy” not a vaccine, as it lacks any antigen. In a TED talk, the Chief Medical Officer of Moderna referred to mRNA “vaccines” as “hacking the software of life”. It is far too early to determine whether the Moderna “vaccine” is even safe or effective, never mind Nobel Prize worthy.

    Leave a Reply
    • Wall Street Wire

      Thanks for sharing your thoughts. The article above, about the “noble-price worthy” vaccine, relates to cancer treatment, not COVID-19. This article wasn’t about the mRNA vaccine.

      Leave a Reply
  2. Ken Frazier

    My wife, Age 80 and myself age 83 just finished taking our Moderna shots. Both doing well. Thank You.

    Leave a Reply
    • Wall Street Wire

      Glad to hear it. Thanks for sharing!

      Leave a Reply